抗凝治疗的演变
The evolution of anticoagulant therapy.
作者信息
Franchini Massimo, Liumbruno Giancarlo M, Bonfanti Carlo, Lippi Giuseppe
机构信息
Department of Haematology and Transfusion Medicine, Carlo Poma Hospital, Mantua, Italy.
Italian National Blood Centre, National Institute of Health, Rome, Italy.
出版信息
Blood Transfus. 2016 Mar;14(2):175-84. doi: 10.2450/2015.0096-15. Epub 2015 Dec 16.
Abstract
Arterial and venous thromboembolism are leading causes of morbidity and mortality around the world. For almost 70 years, heparins (unfractionated heparin and low molecular weight heparins) and vitamin K antagonists have been the leading therapeutic medical options for the treatment and prevention of thromboembolic disorders. Nevertheless, the many limitations of these traditional anticoagulants have fuelled the search for novel agents over the past 15 years, and a new class of oral anticoagulants that specifically target activated factor X and thrombin has been developed and is now commercially available. In this narrative review, the evolution of anticoagulant therapy is summarised, with a focus on newer oral anticoagulants.
摘要
动脉和静脉血栓栓塞是全球发病和死亡的主要原因。近70年来，肝素（普通肝素和低分子肝素）和维生素K拮抗剂一直是治疗和预防血栓栓塞性疾病的主要治疗药物选择。然而，这些传统抗凝剂的诸多局限性促使人们在过去15年中寻找新型药物，现已开发出一类专门针对活化因子X和凝血酶的新型口服抗凝剂并已上市。在这篇叙述性综述中，总结了抗凝治疗的演变，重点是新型口服抗凝剂。
相似文献
1
The evolution of anticoagulant therapy.抗凝治疗的演变
Blood Transfus. 2016 Mar;14(2):175-84. doi: 10.2450/2015.0096-15. Epub 2015 Dec 16.
2
Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.非维生素K拮抗剂口服抗凝药在静脉血栓栓塞管理中的获益-风险概况
Thromb Haemost. 2015 Feb;113(2):231-46. doi: 10.1160/TH14-06-0484. Epub 2014 Oct 16.
3
Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update.评估直接口服抗凝剂治疗癌症相关性血栓：更新。
J Thromb Thrombolysis. 2019 Apr;47(3):409-419. doi: 10.1007/s11239-018-1783-2.
4
Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism.直接口服抗凝剂在静脉血栓栓塞症治疗中的应用。
Hematol Oncol Clin North Am. 2016 Oct;30(5):1035-51. doi: 10.1016/j.hoc.2016.05.008. Epub 2016 Jul 20.
5
Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?直接凝血蛋白抑制剂——抗凝治疗肝素和低分子肝素时代的终结？
Thromb Haemost. 2009 Nov;102(5):892-9. doi: 10.1160/TH09-02-0134.
6
Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism.贝曲西班简介及其在预防和治疗静脉血栓栓塞中的潜力。
Vasc Health Risk Manag. 2015 Jun 26;11:343-51. doi: 10.2147/VHRM.S63060. eCollection 2015.
7
Factor Xa and thrombin as targets for new oral anticoagulants.Xa 因子和凝血酶作为新型口服抗凝剂的作用靶点。
Thromb Res. 2011 Jan;127 Suppl 2:S5-S12. doi: 10.1016/S0049-3848(10)70147-X.
8
Cancer-associated thrombosis: investigating the role of new oral anticoagulants.癌症相关血栓形成：探究新型口服抗凝剂的作用
Thromb Res. 2015 May;135(5):777-81. doi: 10.1016/j.thromres.2015.02.024. Epub 2015 Feb 26.
9
Insights into direct anticoagulants.直接凝血酶抑制剂的见解。
Blood Coagul Fibrinolysis. 2015 Jul;26(5):492-8. doi: 10.1097/MBC.0000000000000291.
10
Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations.非维生素 K 拮抗剂口服抗凝剂（NOACs）：临床证据和治疗考虑。
Postgrad Med J. 2014 Sep;90(1067):520-8. doi: 10.1136/postgradmedj-2014-132605. Epub 2014 Aug 1.
引用本文的文献
1
A Novel Human Anti-FV mAb as a Potential Tool for Diagnostic and Coagulation Inhibitory Approaches.一种新型人抗FV单克隆抗体作为诊断和凝血抑制方法的潜在工具。
Int J Mol Sci. 2025 Mar 18;26(6):2721. doi: 10.3390/ijms26062721.
2
Update on Patient Self-Testing with Portable and Wearable Devices: Advantages and Limitations.便携式和可穿戴设备用于患者自我检测的最新进展：优势与局限
Diagnostics (Basel). 2024 Sep 13;14(18):2037. doi: 10.3390/diagnostics14182037.
3
Factor Xa inhibitors versus low-molecular-weight heparin for preventing coagulopathy following COVID-19: a systematic review and meta-analysis of randomized controlled trials.新型冠状病毒肺炎后预防凝血病的Xa因子抑制剂与低分子量肝素对比：一项随机对照试验的系统评价和荟萃分析
Ann Med Surg (Lond). 2024 May 8;86(7):4075-4082. doi: 10.1097/MS9.0000000000002079. eCollection 2024 Jul.
4
Understanding Antithrombotic Agents for Rehabilitation Therapy: A Comprehensive Narrative Review.康复治疗中抗血栓药物的理解：一项全面的叙述性综述
Cureus. 2024 Apr 15;16(4):e58302. doi: 10.7759/cureus.58302. eCollection 2024 Apr.
5
Abelacimab: A leap forward in anticoagulation with FXI and FXIa Inhibition.阿贝西单抗：通过抑制因子XI和因子XIa实现抗凝治疗的重大进展。
Curr Res Pharmacol Drug Discov. 2024 Mar 14;6:100179. doi: 10.1016/j.crphar.2024.100179. eCollection 2024.
6
Anticoagulant drugs for patients with atrial fibrillation on dialysis: a systematic analysis and network meta-analysis.透析患者心房颤动的抗凝药物：系统分析与网状Meta分析
Front Pharmacol. 2023 Dec 15;14:1320939. doi: 10.3389/fphar.2023.1320939. eCollection 2023.
7
Pharmacogenomic Considerations for Anticoagulant Prescription in Patients with Hereditary Haemorrhagic Telangiectasia.遗传性出血性毛细血管扩张症患者抗凝处方的药物基因组学考量
J Clin Med. 2023 Dec 15;12(24):7710. doi: 10.3390/jcm12247710.
8
Systematic review on the effects of the discontinuation of the anticoagulant therapy and the postoperative bleeding, in patients under new oral anticoagulants after dental extraction.关于拔牙后使用新型口服抗凝剂的患者停用抗凝治疗与术后出血影响的系统评价
J Clin Exp Dent. 2023 Apr 1;15(4):e338-e345. doi: 10.4317/jced.60122. eCollection 2023 Apr.
9
Preparation of Apixaban Solid Dispersion for the Enhancement of Apixaban Solubility and Permeability.用于提高阿哌沙班溶解度和渗透性的阿哌沙班固体分散体的制备。
Pharmaceutics. 2023 Mar 10;15(3):907. doi: 10.3390/pharmaceutics15030907.
10
A Descriptive Analysis of Direct Oral Anticoagulant Drugs Dosing Errors Based on Spontaneous Reports from the EudraVigilance Database.基于欧洲药品管理局药物警戒数据库自发报告的直接口服抗凝药物剂量错误描述性分析
Pharmaceuticals (Basel). 2023 Mar 17;16(3):455. doi: 10.3390/ph16030455.
本文引用的文献
1
Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study.口服抗凝剂相关的胃肠道出血风险：基于人群的回顾性队列研究。
BMJ. 2015 Apr 24;350:h1585. doi: 10.1136/bmj.h1585.
2
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.达比加群、利伐沙班和华法林导致胃肠道出血的比较风险：基于人群的队列研究。
BMJ. 2015 Apr 24;350:h1857. doi: 10.1136/bmj.h1857.
3
Which patients with venous thromboembolism should receive non-vitamin K antagonist oral anticoagulants? The majority.哪些静脉血栓栓塞患者应接受非维生素K拮抗剂口服抗凝药治疗？大多数患者。
Blood Transfus. 2015 Apr;13(2):181-3. doi: 10.2450/2015.0057-15.
4
The treatment of venous thromboembolism with novel oral anticoagulants: warnings and limitations.新型口服抗凝剂治疗静脉血栓栓塞症：警告与局限性
Blood Transfus. 2015 Apr;13(2):178-80. doi: 10.2450/2015.0002-15.
5
The use of novel oral anticoagulants: the debate continues!新型口服抗凝药的应用：争论仍在继续！
Blood Transfus. 2015 Apr;13(2):170-1. doi: 10.2450/2015.0059-15.
6
Low-molecular-weight heparins and cancer: focus on antitumoral effect.低分子量肝素与癌症：聚焦抗肿瘤作用。
Ann Med. 2015 Mar;47(2):116-21. doi: 10.3109/07853890.2015.1004361. Epub 2015 Mar 13.
7
Risk of bleeding with dabigatran in atrial fibrillation.达比加群酯在心房颤动中的出血风险。
JAMA Intern Med. 2015 Jan;175(1):18-24. doi: 10.1001/jamainternmed.2014.5398.
8
Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.口服Xa因子抑制剂依度沙班与依诺肝素在全膝关节置换术后预防血栓形成方面的安全性和有效性：STARS E-3试验
Thromb Res. 2014 Dec;134(6):1198-204. doi: 10.1016/j.thromres.2014.09.011. Epub 2014 Sep 21.
9
Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?直接口服抗凝剂（DOACs）实验室评估的最新指南与建议：是否存在共识？
Clin Chem Lab Med. 2015 Feb;53(2):185-97. doi: 10.1515/cclm-2014-0767.
10
The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis.目标特异性口服抗凝剂治疗患者出血并发症的影响：系统评价和荟萃分析。
Blood. 2014 Oct 9;124(15):2450-8. doi: 10.1182/blood-2014-07-590323. Epub 2014 Aug 22.
Zotero 插件